Medical Director of Clinical Research
Oncology
Dr. Kamalesh K. Sankhala, MD
|
|
Give Review
Kamalesh Sankhala practices Oncology. He researched medicine at Dr. S.N. Medical College. He has 3 awards "CMS Meaningful Use Stage 1 Certification", "AACR-NCI Scholarship for “Molecular Biology in Clinical Oncology†workshop" and "The American Society of Clinical Oncology Foundation Merit Award". Kamalesh K. Sankhala is a published physician as well. He has 22 publications published. The latest was: A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma. Dr. Kamalesh K. Sankhala is registered with Medicare and accepts Medicare payments.
Publications
- Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid Tumors.
- A phase 1B/2 study of aldoxorubicin in patients with soft tissue Sarcoma.
- Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib...
- Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer.
- A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid Tumors.
- Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory Acute myeloid leukemia.
- Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas.
- Heat Shock Proteins: A Potential AntiCancer Target.
- Review: desmoplastic Small round cell tumor: current treatment approach and role of targeted therapy.
- The emerging safety profile of mTOR inhibitors, a novel class of antiCancer agents.
- Targeting the mTOR pathway using deforolimus in Cancer therapy.
- Acute lymphoblastic leukemia presenting with avascular necrosis of the elbow.
- Deforolimus (AP23573) a novel mTOR inhibitor in clinical development.
- Future options for imatinib mesilate-resistant Tumors.
- The emerging role of mammalian target of rapamycin inhibitors in the treatment of Sarcomas.
- Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin.
- Potential of mTOR inhibitors as therapeutic agents in hematological Malignancies.
- Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid Tumors.
- Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.
- Targeting Sarcomas: novel biological agents and future perspectives.
- Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced...
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- Advantage Preferred DirectAccess Plus PPO
- Blue Cross Blue Shield of California PPO
- Pathway X Direct Access PPO
- Pathway X Tiered Direct Access
- Select PPO
- Access Plus Savenet
- Basic Exclusive PPO for Small Business
- Basic PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- CoreSource
- Golden Rule
- Covered California - Bronze PPO
- Health Net PPO
- Individual and Family PPO
- HealthSmart
- Humana
- Mail Handlers Benefit Plan (MHBP)
- Medicaid
- Medicare MCR
- Molina
- Heritage Signature
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
- AACR-NCI Scholarship for “Molecular Biology in Clinical Oncology†workshop
- The American Society of Clinical Oncology Foundation Merit Award
Education
-
University of Texas Health Science Center -
Dr. S.N. Medical College
Drug Facts
| NPI NUMBER | 1225214174 | |
| NPPES Provider LastName | SANKHALA | |
| NPPES Provider FirstName | KAMALESH | |
| NPPES Provider ZIPCode | 904034803 | |
| NPPES Provider State | CA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 90.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1225214174 |
| Last Name Of The Provider | SANKHALA |
| First Name Of The Provider | KAMALESH |
| View All |
Similar Doctors
|
Dr. Sant P. Chawla, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Daniel J. Lieber, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rena D. Callahan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Omid Hamid, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Andrew E. Hendifar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert I. Lehrer, MD
This Doctor is OpenDoctor Recommended.
|